Clinical and Experimental Nephrology

, Volume 18, Issue 4, pp 655–661 | Cite as

Tolvaptan increases urine and ultrafiltration volume for patients with oliguria undergoing peritoneal dialysis

  • Tohru Iwahori
  • Masatoshi Esaki
  • Hayao Hinoue
  • Shinga Esaki
  • Yukumi Esaki
Original Article
First Online:
Received:
Accepted:

Abstract

Background

Hypoalbuminemia caused by peritoneal dialysate protein loss, frequently occurs in patients on peritoneal dialysis (PD) and is associated with an increased risk of death. We investigate whether PD dialysis exchange volume (PD volume) could be reduced with tolvaptan (TVP) through increased urine volume (UV).

Methods

The study included 11 stable patients with oliguria undergoing PD. The following parameters were examined—diuretic response and the effect of TVP on peritoneal ultrafiltration (UF), body weight, serum albumin, sodium, arm muscle area (AMA), PD volume, dialysis efficiency calculator (K t/V), and urine and serum osmolarity (OSM).

Results

The average UV increased from 428 ± 178 to 906 ± 285 mL (p = 0.018 by paired t test). Average weekly PD volume decreased from 28,836 ± 5,699 to 23,872 ± 3,569 mL (p = 0.04 by paired t test). Average UF increased from 283 ± 147 to 575 ± 135 mL (p = 0.019 by paired t test). On the other hand, there was no significant difference in the average dialysate K t/V before and after TVP treatment. Serum sodium, AMA, and serum albumin levels were not statistically different before and after TVP treatment. The urine and serum OSM ratio of effective cases before TVP treatment was higher than that of ineffective cases (p = 0.024 by unpaired t test).

Conclusion

Our results indicate that TVP is useful for patients on continuous ambulatory PD who have oliguria and high urine osmolarity. Furthermore, we can reduce PD volume to maintain their nutritional status.

Keywords

Tolvaptan CAPD Urine volume Ultrafiltration PD dialysis exchange volume us-OSM ratio Kt/V AMA 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

We are very grateful to Medical Engineering staff for assistance with dialysis efficiency and nutrition status.

Conflict of interest

None.

References

  1. 1.
    Chaudhary K, Sangha H, Khanna R. Peritoneal dialysis first: rationale. Clin J Am Soc Nephrol. 2011;6:447–56.PubMedCrossRefGoogle Scholar
  2. 2.
    Tjiong HL, Swart R, van den Berg JW, Fieren MW. Amino Acid-based peritoneal dialysis solutions for malnutrition: new perspectives. Perit Dial Int. 2009;29:384–93.PubMedGoogle Scholar
  3. 3.
    Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25(Suppl 1):S33–45.PubMedCrossRefGoogle Scholar
  4. 4.
    Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol. 2013;61:169–74.PubMedCrossRefGoogle Scholar
  5. 5.
    Watanabe K, Dohi K, Sugimoto T, et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol. 2012;60:462–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Josiassen RC, Curtis J, Filmyer DM, et al. Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders. Expert Opin Pharmacother. 2010;11:637–48.PubMedCrossRefGoogle Scholar
  7. 7.
    Aperis G, Alivanis P. Tolvaptan: a new therapeutic agent. Rev Recent Clin Trials. 2011;6:177–88.PubMedCrossRefGoogle Scholar
  8. 8.
    Jones CH, Wells L, Stoves J, et al. Can a reduction in extracellular fluid volume result in increased serum albumin in peritoneal dialysis patients? Am J Kidney Dis. 2002;39:872–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Struijk DG, Krediet RT, Koomen GC, et al. The effect of serum albumin at the start of continuous ambulatory peritoneal dialysis treatment on patient survival. Perit Dial Int. 1994;14:121–6.PubMedGoogle Scholar
  10. 10.
    Blumenkrantz MJ, Gahl GM, Kopple JD, et al. Protein losses during peritoneal dialysis. Kidney Int. 1981;19:593–602.PubMedCrossRefGoogle Scholar
  11. 11.
    Ates K, Oztemel A, Nergizoglu G, et al. Peritoneal protein losses do not have a significant impact on nutritional status in CAPD patients. Perit Dial Int. 2001;21:519–22.PubMedGoogle Scholar
  12. 12.
    Hakemi MS, Golbabaei M, Nassiri A, et al. Predictors of patient survival in continuous ambulatory peritoneal dialysis: 10-year experience in 2 major centers in Tehran. Iran J Kidney Dis. 2010;4:44–9.PubMedGoogle Scholar
  13. 13.
    Testani JM, Cappola TP, Brensinger CM, et al. Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol. 2011;58:375–82.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Nunez J, Nunez E, Minana G et al. Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure. Eur J Heart Fail. 2012;14(9):974–84.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Hirano T, Yamamura Y, Nakamura S, et al. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288–94.PubMedGoogle Scholar
  16. 16.
    Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.PubMedCrossRefGoogle Scholar
  17. 17.
    Schweiger TA, Zdanowicz MM. Vasopressin-receptor antagonists in heart failure. Am J Health Syst Pharm. 2008;65:807–17.PubMedCrossRefGoogle Scholar
  18. 18.
    Shoaf SE, Bramer SL, Bricmont P, Zimmer CA. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol. 2007;50:213–22.PubMedCrossRefGoogle Scholar
  19. 19.
    Suzuki H, Inoue T, Kobayashi K, et al. The newly developed calcium antagonist, azelnidipine, increases drain volume in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial. 2006;22:18–23.PubMedGoogle Scholar
  20. 20.
    Wang T, Cheng HH, Heimburger O, et al. Intraperitoneal atrial natriuretic peptide increases peritoneal fluid and solute removal. Kidney Int. 2001;60:513–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Boyd JH, Holmes CL, Wang Y, et al. Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R. Resuscitation. 2008;79:325–31.PubMedCrossRefGoogle Scholar
  22. 22.
    Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371:1624–32.PubMedCrossRefGoogle Scholar
  23. 23.
    Imamura T, Kinugawa K, Shiga T, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients–association between non-responders and chronic kidney disease. Circ J. 2013;77:397–404.PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2013

Authors and Affiliations

  • Tohru Iwahori
    • 1
  • Masatoshi Esaki
    • 2
  • Hayao Hinoue
    • 3
  • Shinga Esaki
    • 1
  • Yukumi Esaki
    • 2
  1. 1.Department of Nephrology and ImmunologyKoyukai Memorial HospitalChibaJapan
  2. 2.Department of SurgeryKoyukai Memorial HospitalChibaJapan
  3. 3.Department of SurgeryInage HospitalChibaJapan

Personalised recommendations